Investment Rating - The report recommends a focus on the company, indicating that it is undervalued with a reasonable valuation range of over HKD 25 billion [21]. Core Insights - The company has transitioned from traditional generic drugs to a dual-driven strategy focusing on "aesthetic medicine and innovative drugs," leading to a significant revenue increase in the aesthetic segment [21]. - The aesthetic medicine segment saw a revenue increase of 81% year-on-year in the first half of 2025, contributing significantly to the company's overall revenue growth [4][11]. - The innovative drug segment is expected to enter a revenue realization phase with the commercialization of new drugs, enhancing the company's financial outlook [12][16]. Summary by Sections Aesthetic Medicine - In H1 2025, aesthetic medicine revenue increased by 81% to HKD 5.9 billion, with a gross margin improvement of 8 percentage points to 73% [4][11]. - The core product, Letybo (botulinum toxin), has a market penetration of less than 2% in China, indicating substantial growth potential compared to higher penetration rates in the US and South Korea [5]. - The company has three major products approved in 2025, including facial fillers and water light needles, which are expected to drive significant sales growth [9][10]. Innovative Drugs - The innovative drug segment reported a 30% revenue increase to HKD 0.17 billion in H1 2025, with a focus on gastrointestinal and oncology treatments [12]. - The company has successfully commercialized its first innovative PPI drug, which is expected to maintain its price in the national basic medical insurance directory [12][14]. - The company holds a 49.13% stake in Xuan Zhu Bio, which has a market capitalization of HKD 34.5 billion, further enhancing its financial position [12]. Biopharmaceuticals - The biopharmaceutical segment, focusing on diabetes, has a comprehensive pipeline with over 20 products, and revenue is expected to see explosive growth in the next 2-3 years [17][18]. - The company reported a 40-fold increase in revenue to HKD 0.39 billion in H1 2025, with a focus on insulin and innovative diabetes treatments [17][18]. Generic Drugs - Generic drug revenue decreased by 16% to HKD 5.0 billion in H1 2025, accounting for 44% of total revenue, but the impact is expected to lessen as aesthetic and innovative drug segments grow [19]. - Key products include Clinao (a unique injection) and a mucosal solution for children, which are positioned to capture niche markets [19]. Profit Forecast - The company is expected to turn profitable in 2025, with significant revenue growth driven by aesthetic and innovative drugs, alongside reduced R&D expenses [20]. - The company has maintained a high dividend payout ratio of 89% in H1 2025, reflecting strong cash flow management [20].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][56]. Core Insights - The company is a leading player in the snack retail industry, with significant growth in revenue and profit projected for the coming years. Revenue is expected to reach RMB 656.97 billion in 2025, RMB 837.49 billion in 2026, and RMB 925.80 billion in 2027, with corresponding growth rates of 66.98%, 27.48%, and 10.54% respectively. Net profit is forecasted to be RMB 23.01 billion, RMB 34.23 billion, and RMB 42.85 billion for the same years, reflecting growth rates of 176.05%, 48.73%, and 25.19% respectively [2][56]. Summary by Sections Company Overview - The company, founded in 2016, has rapidly expanded its store count to 21,041 by November 2025, with 59% of stores located in county and town areas. The company achieved a GMV of RMB 555 billion in 2024 and RMB 661 billion in the first three quarters of 2025, marking year-on-year increases of 262% and 74% respectively [7][15]. Store Expansion and Performance - The company has seen a continuous increase in store numbers, from 1,902 in 2022 to 21,041 by November 2025. The average daily order volume per store has also risen from 385 to 481 orders during the same period, with a year-on-year increase of 4.1% [15][21]. Financial Performance - The company reported revenues of RMB 393.4 billion and RMB 463.7 billion for 2024 and the first three quarters of 2025, respectively, with year-on-year growth of 282% and 75%. Net profits for the same periods were RMB 8.29 billion and RMB 15.59 billion, reflecting growth rates of 281% and 219% [43][44]. Profitability Metrics - The company's net profit margin improved from 1.67% in 2022 to 3.36% in the first three quarters of 2025. The adjusted net profit margin also increased from 1.90% to 3.90% during the same period, indicating enhanced profitability [44][56]. Future Projections - The report forecasts significant revenue and profit growth for the company, with expected revenues of RMB 656.97 billion, RMB 837.49 billion, and RMB 925.80 billion for 2025, 2026, and 2027, respectively. The corresponding net profits are projected to be RMB 23.01 billion, RMB 34.23 billion, and RMB 42.85 billion [2][56].

[Table_Title] 【广发批零社服&海外】百胜中国 （09987.HK/YUMC.N） Q4 同店与利润率优化超预期，龙头韧性凸显 [Table_Summary] 核心观点： 盈利预测：（货币单位为美元，汇率采用 1 港元=0.13 美元） | [单位Table_Finance] :百万元 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 11303 | 11797 | 12449 | 13142 | 13862 | | 增长率（ % ） | 3.0% | 4.4% | 5.5% | 5.6% | 5.5% | | EBITDA | 1638 | 1737 | 1859 | 1977 | 2099 | | 归母净利润 | 911 | 929 | 1002 | 1080 | 1157 | | 增长率（ ） % | 10.2% | 2.0% | 7.8% | 7.8% | 7.1% | | EPS（元/股） | 2.33 | 2.50 | 2.87 | 3.30 | 3.72 | ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][56]. Core Insights - The company is a leading player in the snack retail industry, with significant growth in revenue and profit projected for the coming years. Revenue is expected to reach RMB 656.97 billion in 2025, RMB 837.49 billion in 2026, and RMB 925.80 billion in 2027, with corresponding growth rates of 66.98%, 27.48%, and 10.54% respectively. Net profit is forecasted to be RMB 23.01 billion, RMB 34.23 billion, and RMB 42.85 billion for the same years, reflecting growth rates of 176.05%, 48.73%, and 25.19% respectively [2][56]. Company Overview - The company, founded in 2016, has rapidly expanded its store count from 1,902 in 2022 to 21,041 by November 2025, with a significant portion of stores located in county and town areas. The company achieved a GMV of RMB 555 billion in 2024 and RMB 661 billion in the first three quarters of 2025, marking year-on-year increases of 262% and 74% respectively [7][15]. Store Expansion and Performance - The company continues to expand its store network, primarily through franchising. The average daily order volume per store has increased from 385 in 2022 to 481 in the first three quarters of 2025, with total orders reaching 2.129 billion, a 97.3% increase year-on-year. The average GMV per store is also on the rise, with the company maintaining a low closure rate for franchise stores [21][37]. Financial Performance - The company has demonstrated strong revenue and profit growth, with revenues of RMB 393.4 billion and RMB 463.7 billion for 2024 and the first three quarters of 2025, respectively, reflecting year-on-year growth of 282% and 75%. The net profit for the same periods reached RMB 8.29 billion and RMB 15.59 billion, with adjusted profits showing similar growth [43][44]. Profitability Metrics - The company's net profit margin improved from 1.67% in 2022 to 3.36% in the first three quarters of 2025, while the adjusted net profit margin rose from 1.90% to 3.90%. The gross margin also increased from 7.45% to 9.73% during the same period, indicating enhanced profitability [44][50]. Future Projections - The report outlines optimistic projections for the company's financial performance, with significant revenue and profit growth anticipated through 2027. The expected earnings per share (EPS) are projected to be RMB 10.68, RMB 15.88, and RMB 19.88 for 2025, 2026, and 2027, respectively [56][57].

本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 2026 年 2 月 6 日 同程旅行 780 HK 本文内容由 Ryan Lee (李昊谦) 提供 中信证券财富管理(香港) 产品及投资方案部 中国互联网行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 纪律重于叙事逻辑 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 5 日发布的题为《Discipline over narrative》的报告，尽管美国有关具备自主行动能力的人工智能取代包括在线旅行社（ OTAs）在内的交易型平台的 叙事广泛流传，但中信里昂认为该风险在中国不会立即显现，主要因 OTA 对供应链有更严格的控制。分析预计公司 的酒店管理业务将在 2026 年营收增长中占据更大比重，但可能伴随着前期的支出增加。分析指出，同程不太可能受 益于携程反垄断调查，因为二者共享库存池。 谷歌新推出的自动浏览航班预订功能引发了全 ...

Investment Rating - The report maintains a "Buy" rating for the company [6][24]. Core Insights - The company is expected to expand its store count significantly, with a long-term target of 35,000 stores, driven by a unique "onion ring" expansion strategy and strong supply chain capabilities [2][14]. - The company is transitioning from a tea beverage leader to a multi-category pioneer, introducing new product lines such as coffee, desserts, and HPP juices, which are expected to enhance store efficiency and broaden customer demographics [3][19]. - The company is projected to achieve a net profit of 2.913 billion RMB in 2026, reflecting a year-on-year growth of 17%, with a net profit margin of 18.3% [4][24]. Summary by Sections Store Expansion Potential - The company has a long-term store expansion potential of approximately 35,375 stores, based on regional density improvements and supply-demand growth perspectives [2][14]. - The company has entered new provinces and strengthened its competitive barriers in existing regions, enhancing brand recognition and supply chain synergy [12][13]. Product and Store Model Innovation - The company has accelerated its transformation into a multi-category "beverage convenience store," effectively filling gaps in non-peak consumption periods and expanding its customer base [3][19]. - The introduction of the 6.0 store model aims to enhance brand quality and customer experience, with a focus on optimizing dining experiences and increasing in-store consumption [21][22]. Financial Projections and Valuation - The company’s adjusted net profit forecasts for 2025, 2026, and 2027 are 2.486 billion, 2.913 billion, and 3.693 billion RMB, respectively, with corresponding adjusted EPS of 1.05, 1.22, and 1.55 RMB [5][10]. - The target price has been raised to 36.73 HKD, reflecting a 27x PE ratio for 2026, indicating a strong growth outlook despite potential short-term challenges [24][26].

Investment Rating - The report maintains an "Accumulate" rating for Yum China (9987.HK) [1] Core Insights - In Q4 2025, the company achieved revenue of $2.823 billion, a 9% increase year-over-year, with operating profit rising by 25% to $187 million, and net profit attributable to shareholders increasing by 24% to $140 million. For the entire year, revenue reached $11.797 billion, up 4%, with operating profit at $1.290 billion (+11%) and net profit at $929 million (+2%) [2] - The company returned $539 million to shareholders in Q4 2025, totaling $1.5 billion for the year, with plans to maintain this level of shareholder return in 2026 [2] Summary by Sections Same-Store Sales and Store Expansion - The company reported same-store sales growth for three consecutive quarters, with system sales and same-store sales increasing by 7% and 3% year-over-year in Q4 2025, respectively. A total of 587 new stores were added in the quarter, bringing the annual total to 1,706 new stores, with 31% being franchise stores [3] - By brand, KFC saw system sales and same-store sales growth of 8% and 3% in Q4 2025, respectively, with 357 new stores opened. For the year, KFC's system sales and same-store sales grew by 5% and 1%, respectively, with 1,349 new stores [3] - Pizza Hut experienced system sales and same-store sales growth of 6% and 1% in Q4 2025, with 146 new stores opened. For the year, system sales and same-store sales grew by 4% and 1%, respectively, with 444 new stores [3] New Store Formats and Innovations - The company is expanding its product offerings and store formats to reach a broader customer base. K Coffee and KPRO have shown rapid growth, with K Coffee in 2,200 stores and KPRO expected to double to over 400 stores in 2026. Pizza Hut has successfully entered around 100 new towns with the WOW store model [4] - The company has introduced the "Twin Stars" model, placing KFC and Pizza Hut stores adjacent to each other to penetrate lower-tier markets at a lower cost, with approximately 40 pairs of "Twin Stars" stores opened and plans for accelerated expansion in 2026 [4] Cost Management and Profitability - In Q4 2025, the company's operating profit margin and restaurant profit margin improved to 6.6% and 13.0%, respectively, benefiting from operational efficiencies and favorable raw material prices. KFC's operating profit margin was 10.5%, while Pizza Hut's was 3.7% [5] - The company reported a decrease in the proportion of food and packaging costs by 0.3 percentage points year-over-year, while labor costs increased by 1.2 percentage points. Rental and other expenses decreased by 1.6 percentage points, with delivery sales accounting for 53% of total sales, an increase of 11 percentage points [5] Financial Forecast and Valuation - The report adjusts previous profit forecasts and introduces projections for 2028, estimating revenues of $12.522 billion, $13.264 billion, and $13.983 billion for 2026, 2027, and 2028, respectively. Net profits are projected at $1.015 billion, $1.127 billion, and $1.228 billion for the same years [6] - The latest stock price corresponds to a price-to-earnings ratio of 19, 17, and 16 times for 2026, 2027, and 2028, respectively, maintaining the "Accumulate" rating [6]

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (growth rate of 21.3%) - 2025E: RMB 15,426 million (growth rate of 25.8%) - 2026E: RMB 15,600 million (growth rate of 1.1%) - 2027E: RMB 17,644 million (growth rate of 13.1%) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (growth rate of 33.4%) - 2025E: RMB 5,434 million (growth rate of 24.3%) - 2026E: RMB 4,739 million (decline of 12.8%) - 2027E: RMB 5,828 million (growth rate of 23.0%) [6][12] - The company’s earnings per share (EPS) projections are: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12] Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting a potential upside from the current price of HKD 36.62 [4][7].

[Table_Page] 公司深度研究|汽车与汽车零部件 证券研究报告 | [Table_Title] 【广发汽车&电新&海外】小鹏汽 | | --- | | 车-W(09868.HK)/小鹏汽车(XPEV) | | 十载磨砺成体系，多维增长引擎或将驱动 | | 价值重估 | [Table_Summary] 核心观点： | EBITDA | -9,307 | -4,523 | 185 | 3,590 | 6,812 | | --- | --- | --- | --- | --- | --- | | 归母净利润 | -10,431 | -5,761 | -1,647 | 2,045 | 4,739 | | 增长率（ % ） | - | - | - | - | 131.7% | | EPS（元/股） | -5.53 | -3.03 | -0.86 | 1.07 | 2.48 | | 市盈率（P/E） | - | - | - | 56.0 | 24.2 | | ROE（%） | -28.7% | -18.4% | -5.6% | 6.5% | 13.1% | | EV/EBITDA | - | - | 500.8 ...

中集安瑞科(03899):料印尼项目最多贡献7,000万人民币利润,予"增持"评级 该行预期有关进展将进一步提振市场对公司的情绪，因项目反映公司新业务举措的海外扩张正从愿景迈向 实际执行阶段。同时，该项目是公司第5个焦炉煤气项目，增强了其长远持续增长的能见度，缓解了投资者先 前对于净利润增长放缓的忧虑，因公司的三项新业务均为项目制(project-based)。 摩根大通 摩根大通发布研报称，中集安瑞科(11.71,-0.33,-2.74%)(03899)公布其在印尼的首个海外焦炉煤气项 目。该行估计，若项目达至最高产能，可为公司贡献约7,000万元人民币的利润，约占2025财年预测净利润的 6%;现予中集安瑞科"增持"评级，目标价12港元。 ...